Study of a new drug combo for children with a certain type of brain tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have medulloblastoma that is Group 3 or Group 4, and it has come back or is getting worse.
- You are between 3 and 18 years old.
- You can swallow capsules or tablets.
- You must be able to have a body surface area (a measure of your size) between 0.4 and 2.5 square meters.
- If you've had previous treatments, you need to have recovered from their side effects and wait the required time before joining.
- You have not had a CDK8 inhibitor or an mTOR inhibitor (like everolimus) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
This trial tests two drugs, axitinib and etoposide, taken by mouth to treat children and young adults with medulloblastoma or ependymoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Hear when a new Medulloblastoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.